Mike Zogby is moderating “Inside View: Legal and Ethical Considerations for In-House Counsel,” a corporate roundtable panel discussion addressing the legal and ethical challenges and trends faced by in-house attorneys at pharmaceutical, biotech and medical device companies in the midst of a global pandemic. Panelists include inside counsel from Eli Lilly, Daiichi Sankyo, Novo Nordisk and Johnson & Johnson.
With reference to ABA Model Rules 1.1 through1.5, this interactive program includes a discussion of how to navigate the impact of COVID-19 on multinational mass torts and complex case management, maintaining attorney-client privileged communications, best practices and war stories from managing remote teams and outside counsel through virtual trials and proceedings, the impact of telehealth and remote access on the industry and legal departments, and working with colleagues outside the United States on discovery issues and disputes. This panel also will discuss the importance of ensuring diversity and inclusiveness on litigation and trial teams, as well as trends and predictions for 2021 and beyond.
The ABA is seeking 1.0 hour of Ethics CLE in 60-minute states, and 1.2 hours of Ethics CLE in 50-minute states. The symposium is part of the Current Issues in Pharmaceutical, Medical Device, and Biotech Litigation Virtual Regional CLE Program, presented by the American Bar Association’s Section of Litigation Pharmaceutical, Medical Device, and Biotech Subcommittee and Mass Tort Subcommittee of the Products Liability Committee. Mike is a program organizer, and Faegre Drinker is a sponsor.
In the New Jersey Law Journal’s March 11 “After Hours” edition, the publication highlighted Zogby’s role as a program organizer of the event, his speaking engagement as a panel moderator, and the firm's sponsorship of the two-day event.